4D Molecular Therapeutics will present at the J.P. Morgan Healthcare Conference and hold one-on-one meetings.
Quiver AI Summary
4D Molecular Therapeutics, a late-stage biotechnology company focused on disease-targeted therapeutics, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The management team will present and be available for one-on-one meetings. The company's lead product, 4D-150, aims to transform treatment for blinding retinal vascular diseases, specifically targeting wet age-related macular degeneration and diabetic macular edema with a long-lasting therapy that reduces treatment frequency. Additionally, 4DMT is developing 4D-710, a genetic medicine for cystic fibrosis. All product candidates are still in clinical or preclinical stages and have not received FDA approval. Further information is available on their website.
Potential Positives
- The company will present at the prestigious 44th Annual J.P. Morgan Healthcare Conference, which enhances its visibility and credibility in the biotechnology sector.
- Management's availability for one-on-one meetings may strengthen relationships with investors and stakeholders, fostering confidence in the company's future prospects.
- The announcement highlights the advanced stage of the company's lead product candidate, 4D-150, which is in Phase 3 development for treating wet age-related macular degeneration, indicating progress towards potential market approval.
- 4D-710's unique capability as a genetic medicine for cystic fibrosis could position the company as a leader in innovative treatment options, catering to significant unmet medical needs.
Potential Negatives
- All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority.
FAQ
What is the purpose of 4D Molecular Therapeutics' presentation at the J.P. Morgan Healthcare Conference?
The presentation aims to showcase the company's advancements in biotechnology and therapeutic developments.
When will 4D Molecular Therapeutics present at the conference?
The presentation is scheduled for Wednesday, January 14, 2026, at 7:30 a.m. PT.
Where can I find the webcast of the presentation?
The webcast can be accessed on the “Investors” section of the 4D Molecular Therapeutics website.
What are the main product candidates of 4D Molecular Therapeutics?
The main product candidates are 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis.
Are the company's products approved by the FDA?
No, all product candidates are still in clinical or preclinical development and have not yet received FDA approval.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FDMT Insider Trading Activity
$FDMT insiders have traded $FDMT stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $FDMT stock by insiders over the last 6 months:
- SCOTT BIZILY (Chief Legal Officer) has made 0 purchases and 5 sales selling 10,763 shares for an estimated $109,414.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FDMT Hedge Fund Activity
We have seen 62 institutional investors add shares of $FDMT stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 796,000 shares (+265.3%) to their portfolio in Q3 2025, for an estimated $6,917,240
- VR ADVISER, LLC removed 677,600 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,513,896
- NORGES BANK removed 446,604 shares (-89.2%) from their portfolio in Q2 2025, for an estimated $1,656,900
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND removed 412,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,528,520
- JPMORGAN CHASE & CO removed 374,501 shares (-42.2%) from their portfolio in Q3 2025, for an estimated $3,254,413
- MILLENNIUM MANAGEMENT LLC removed 334,323 shares (-22.5%) from their portfolio in Q3 2025, for an estimated $2,905,266
- DEUTSCHE BANK AG\ added 316,392 shares (+139.4%) to their portfolio in Q3 2025, for an estimated $2,749,446
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FDMT Analyst Ratings
Wall Street analysts have issued reports on $FDMT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 10/21/2025
- Chardan Capital issued a "Buy" rating on 08/12/2025
- Roth Capital issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for $FDMT, check out Quiver Quantitative's $FDMT forecast page.
$FDMT Price Targets
Multiple analysts have issued price targets for $FDMT recently. We have seen 4 analysts offer price targets for $FDMT in the last 6 months, with a median target of $32.5.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $33.0 on 11/11/2025
- Lisa Walter from RBC Capital set a target price of $32.0 on 11/11/2025
- Geulah Livshits from Chardan Capital set a target price of $26.0 on 11/11/2025
- Salveen Richter from Roth Capital set a target price of $38.0 on 08/12/2025
Full Release
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will present at the 44 th Annual J.P. Morgan Healthcare Conference. Members of the management team will also be available for one-on-one meetings.
44
th
Annual J.P. Morgan Healthcare Conference
| Presentation Date: | Wednesday, Jan 14, 2026 |
| Presentation Time: | 7:30 a.m. PT |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at
https://ir.4dmoleculartherapeutics.com/events
.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn .
Contacts:
Media:
Jenn Gordon
dna Communications
[email protected]
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]
